companydata.dkNOVO NORDISK A/S
CVR: 24256790
Secondary names: NOVO TERAPEUTISK LABORATORIUM A/S, NOVO INDUSTRI A/S, NORDISK GENTOFTE A/S
Previous names: NOVO INDUSTRI A/S, NOVO-NORDISK A/S
Novo Nordisk A/S exhibits strong financial health, characterized by robust profitability and significant revenue generation. In 2025, the company reported a revenue of 229.92 billion DKK and a profit of 75.54 billion DKK, indicating a solid profit margin. The revenue trend shows growth from 204.72 billion DKK in 2024 to 290.40 billion DKK, reflecting a strong upward trajectory. With equity standing at 169.90 billion DKK in 2025, the company maintains a healthy equity position, although the slight decline from previous years may warrant attention. As a major player in the pharmaceutical manufacturing industry, Novo Nordisk is well-positioned for continued success.
AI-generated summary
Overview
Details
Contact
Purpose
Selskabets formål er at forske i, udvikle, producere og markedsføre farmaceutiske, medicinske og tekniske produkter og ydelser samt anden dertil knyttet virksomhed efter bestyrelsens nærmere bestemmelse. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 309.1 mia. | 102.4 mia. | 542.9 mia. | 194 mia. | 76343 | |
History
Ownership
Properties
(73)· 21 historic73 properties
Upgrade to Pro to see addresses, building data and ownership details
Management
Directors
Board
Production units (217)
Similar companies
Companies in the same industry and area